Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of anandamide

Drug Metabolism and Disposition

Volumn 38, Issue 11, 2010, Pages 2075-2082

  Pratt Hyatt, Matthew ^a   Zhang, Haoming ^a   Snider, Natasha T ^a   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

19 HYDROXYEICOSATETRAENOIC ACID ETHANOLAMIDE; 5,6 EPOXYEICOSATRIENOIC ACID ETHANOLAMIDE; ANANDAMIDE; CYTOCHROME P450 3A4; DRUG METABOLITE; LEUCINE; PROSTAGLANDIN D SYNTHASE; TESTOSTERONE 6BETA OL; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG; VALINE;

APPETITE; ARTICLE; ATOM; BIOLOGICAL ACTIVITY; CATALYSIS; CONTROLLED STUDY; DRUG METABOLISM; ESCHERICHIA COLI; GENETIC POLYMORPHISM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL;

ARACHIDONIC ACIDS; BINDING SITES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; HUMANS; KINETICS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYUNSATURATED ALKAMIDES; PROTEIN BINDING; RECEPTOR, CANNABINOID, CB2; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TESTOSTERONE;

ESCHERICHIA COLI;

EID: 78049399957     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033712     Document Type: Article

References (30)

1. Bornheim LM, Kim KY, Chen B, and Correia MA (1995) Microsomal cytochrome P450- mediated liver and brain anandamide metabolism. Biochem Pharmacol 50:677-686.
2. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, and Di Marzo V (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 276:12856-12863. (Pubitemid 37385205)
3. Di Marzo V, Bifulco M, and De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784. (Pubitemid 39242829)
4. Domanski TL, Liu J, Harlow GR, and Halpert JR (1998) Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and α-naphthoflavone stimulation. Arch Biochem Biophys 350:223-232.
5. Ducobu J (2005) The endocannabinoid system and the regulation of the metabolism. J Pharm Belg 60:84-88.
6. Ducobu J and Sternon J (2005) Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system. Rev Med Brux 26:165-168. (Pubitemid 40942804)
7. Estabrook RW and Werringloer J (1978) The measurement of difference spectra: application to the cytochromes of microsomes. Methods Enzymol 52:212-220.
8. Felder CC, Dickason-Chesterfield AK, and Moore SA (2006) Cannabinoids biology: the search for new therapeutic targets. Mol Interv 6:149-161.
9. Hanna IH, Teiber JF, Kokones KL, and Hollenberg PF (1998) Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch Biochem Biophys 350:324-332.
10. Herradón E, Martín MI, and López-Miranda V (2007) Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol 152:699-708. (Pubitemid 350034972)
11. Kozak KR and Marnett LJ (2002) Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66:211-220.
12. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutiérrez SO, van der Stelt M, et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88.
13. Morris GM, Goodsell DS, Huey R, and Olson AJ (1996) Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 10:293-304.
14. Nithipatikom K, Grall AJ, Holmes BB, Harder DR, Falck JR, and Campbell WB (2001) Liquid chromatographic-electrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal Biochem 298:327-336.
15. Palmer SL, Khanolkar AD, and Makriyannis A (2000) Natural and synthetic endocannabinoids and their structure-activity relationships. Curr Pharm Des 6:1381-1397.
16. Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, and Shohami E (2005) CB1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition. J Cereb Blood Flow Metab 25:477-484.
17. Parmentier-Batteur S, Jin K, Mao XO, Xie L, and Greenberg DA (2002) Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 22:9771-9775.
18. Richardson JD, Kilo S, and Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111-119. (Pubitemid 28254862)
19. Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, and Navarro M (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40:2-14.
20. Shebley M and Hollenberg PF (2007) Mutation of a single residue (K262R) in P450 2B6 leads to loss of mechanism-based inactivation by phencyclidine. Drug Metab Dispos 35:1365-1371.
21. Simmons DL, Botting RM, and Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387-437.
22. Snider NT, Kornilov AM, Kent UM, and Hollenberg PF (2007) Anandamide metabolism by human liver and kidney microsomal cytochrome P450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J Pharmacol Exp Ther 321:590-597.
23. Snider NT, Nast JA, Tesmer LA, and Hollenberg PF (2009) A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist. Mol Pharmacol 75:965-972.
24. Snider NT, Sikora MJ, Sridar C, Feuerstein TJ, Rae JM, and Hollenberg PF (2008) The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther 327:538-545.
25. Vickers SP and Kennett GA (2005) Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets 6:215-223.
26. Wang A, Yu BN, Luo CH, Tan ZR, Zhou G, Wang LS, Zhang W, Li Z, Liu J, and Zhou HH (2005) Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 60:843-848.
27. Watanabe K, Shimizu T, Iguchi S, Wakatsuka H, Hayashi M, and Hayaishi O (1980) An NADP-linked prostaglandin D dehydrogenase in swine brain. J Biol Chem 255:1779-1782.
28. Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS, Turchin PI, Mark L, Garrison AE, and Valenzano KJ (2005) A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur J Pharmacol 528:65-72.
29. Yamada Y, Metoki N, Yoshida H, Satoh K, Kato K, Hibino T, Yokoi K, Watanabe S, Ichihara S, Aoyagi Y, et al. (2008) Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke 39:2211-2218.
30. 5 inhibits electron transfer from NADPH-cytochrome P450 reductase to ferric cytochrome P450 2B4. J Biol Chem 283:5217-5225.